

References

I-25

1. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. *Transplantation*. 2012;93(3):319-24.
2. Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. *Nephrol Dial Transplant*. 2012 Mar;27(3):1246-51.
3. Centers for Medicare and Medicaid Services (CMS). National Coverage determination (NCD) for apheresis (therapeutic pheresis)(110.14). CMS.gov/medicare-coverage-database/details/ncd-details.aspx.
4. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. *Transplantation*. 2012;93(3):319-324.
5. Muramatsu M, Gonzalez HD, Cacciola R, et al. ABO incompatible renal transplants: Good or bad? *World Journal of Transplants*. 2014;4(1):18-29.
6. Koo TY, Yang J. Current progress in ABO-incompatible kidney transplantation. *Kidney Res Clin Pract*. 2015;34:170-179.
7. Klein C, Brennan DC. HLA and ABO sensitization and desensitization in renal transplantation. UpToDate. Last updated January 23, 2015.
8. Kim IK, VO A, Jordan SC. Transplantation in highly HLA-sensitized patients: challenges and solutions. *Dover Press*. 2014;2014(6):99-107
9. Krishnan NS, Zehnder D, Briggs D, Higgins R. Human leukocyte antigen antibody incompatible renal transplantation. *IJN*. 2014:409-414.
10. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. *Immunological Reviews*. 2014;258: 183–207.
11. Al-Mohaisen MA, Virani SA. Allosensitization in Heart Transplantation: An Overview. *Can J Cardiol*. 2014;161-172.